Literature DB >> 28777121

RAF1 variants causing biventricular hypertrophic cardiomyopathy in two preterm infants: further phenotypic delineation and review of literature.

Danielle Thompson1, Jessica Patrick-Esteve, Jeffrey W Surcouf, Dana Rivera, Bianca Castellanos, Pooja Desai, Christian Lilje, Yves Lacassie, Michael Marble, Regina Zambrano.   

Abstract

Noonan syndrome (NS) is an autosomal dominant disorder characterized by distinctive facial features, short neck, short stature, congenital heart defects, pectus deformities, and variable developmental delays. NS is genetically heterogeneous as pathogenic variants in several genes involved in the Ras/mitogen-activated protein kinase pathway have been associated with a NS phenotype. Overall, 50% of patients harbor pathogenic variants in PTPN11, whereas 3-17% of patients have variants in RAF1. We present two premature neonates with progressive biventricular hypertrophy found to have RAF1 variants in the CR2 domain. Molecular testing in patient 1 revealed a missense variant of a highly conserved residue c.782 C>G (p.P261R). This variant has been reported once with fatal outcome. Patient 2 also had a missense variant in a highly conserved neighboring residue c.770 C>T (p.S257L). This variant has been previously reported, most recently associated with the development of pulmonary arterial hypertension. Both our patients had prenatal findings of polyhydramnios, short long bones, hydrops fetalis, and cardiac anomalies with progressive biventricular hypertrophic cardiomyopathy. Both patients had a lethal outcome. Our findings further support the pathogenicity and lethality of p.P261R, and the need to monitor for pulmonary arterial hypertension in p.S257L. In addition, the second patient was presented with progressive hydrocephalus due to aqueductal stenosis. This could be related to the NS phenotype. More cases with this association are needed to confirm this finding.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28777121     DOI: 10.1097/MCD.0000000000000194

Source DB:  PubMed          Journal:  Clin Dysmorphol        ISSN: 0962-8827            Impact factor:   0.816


  5 in total

Review 1.  [Modern genetic counselling : Practical aspects exemplified by hypertrophic cardiomyopathy].

Authors:  F Czepluch; G Hasenfuß; B Wollnik
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

2.  Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.

Authors:  Fabrice Jaffré; Clint L Miller; Anne Schänzer; Todd Evans; Amy E Roberts; Andreas Hahn; Maria I Kontaridis
Journal:  Circulation       Date:  2019-06-05       Impact factor: 29.690

Review 3.  Lymphatic Abnormalities in Noonan Syndrome Spectrum Disorders: A Systematic Review.

Authors:  Julia Sleutjes; Lotte Kleimeier; Erika Leenders; Willemijn Klein; Jos Draaisma
Journal:  Mol Syndromol       Date:  2021-09-10

4.  RAF-1 Mutation Associated with a Risk for Ventricular Arrhythmias in a Child with Noonan Syndrome and Cardiovascular Pathology.

Authors:  Amalia Făgărășan; Hamida Al Hussein; Simina Elena Ghiragosian Rusu
Journal:  J Crit Care Med (Targu Mures)       Date:  2022-05-12

5.  MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy but Is Insufficient to Revert Pulmonary Vascular Disease.

Authors:  Alessandro Mussa; Diana Carli; Elisa Giorgio; Anna Maria Villar; Simona Cardaropoli; Caterina Carbonara; Maria Francesca Campagnoli; Paolo Galletto; Martina Palumbo; Simone Olivieri; Claudio Isella; Gregor Andelfinger; Marco Tartaglia; Giovanni Botta; Alfredo Brusco; Enzo Medico; Giovanni Battista Ferrero
Journal:  Genes (Basel)       Date:  2021-12-21       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.